Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Stanford University
Ensem Therapeutics
AstraZeneca
Mayo Clinic
Kivu Bioscience Inc.
AstraZeneca
Tubulis GmbH
Eli Lilly and Company
EMD Serono
Sumitomo Pharma America, Inc.
Terremoto Biosciences Inc.
Bristol-Myers Squibb
Seagen Inc.
Radiopharm Theranostics, Ltd
Tizona Therapeutics, Inc
Clasp Therapeutics, Inc.
Exscientia AI Limited
Normunity AccelCo, Inc.
Eli Lilly and Company
Baylor College of Medicine
MacroGenics
SystImmune Inc.
Eli Lilly and Company
Radiopharm Theranostics, Ltd
Innate Pharma
Sichuan Baili Pharmaceutical Co., Ltd.
Var2 Pharmaceuticals
OncoNano Medicine, Inc.
GlaxoSmithKline
Fate Therapeutics
Compass Therapeutics
Tanabe Pharma America, Inc.
MediLink Therapeutics (Suzhou) Co., Ltd.
Volastra Therapeutics, Inc.
AbbVie
Janux Therapeutics
LigaChem Biosciences, Inc.
Scancell Ltd
Nurix Therapeutics, Inc.
A2 Biotherapeutics Inc.
Pure Biologics S.A.
Medicenna Therapeutics, Inc.
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
DualityBio Inc.
Zumutor Biologics Inc.
Simcha IL-18, Inc.
Cancer Research UK
Zhejiang Provincial People's Hospital